Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients.
Ga Hee KimMinjun KimKyuwon KimJung-Bin ParkJi Eun BaekJune Hwa BaeSeung Wook HongSung Wook HwangDong-Hoon YangByong Duk YeSeung Wook HongSeung-Jae MyungSuk-Kyun YangSang Hyoung ParkPublished in: Yonsei medical journal (2024)
The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.